Drug Profile
Trazodone - Angelini Group/Labopharm
Alternative Names: AF-1161; DDS-04A; Oleptro; Trazodone Contramid OAD; Trazodone extended release; Trazodone HCl; Trazodone OAD; Triticum AC; TritticoLatest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator Angelini Group; Labopharm
- Developer Altus Formulation Inc; Angelini Group; Lee's Pharmaceutical
- Class Antidepressants; Erectile dysfunction therapies; Piperazines; Pyridines; Sleep disorder therapies; Small molecules; Triazoles
- Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Major depressive disorder
- Phase II Diabetic neuropathies; Insomnia
- Preclinical Neurological disorders
Most Recent Events
- 17 Feb 2023 Launched for Major depressive disorder in Bulgaria (PO) (before February 2023) (EudraCT2021-005007-12)
- 17 Feb 2023 Registered for Major depressive disorder in Bulgaria (PO) (before February 2023)
- 22 Mar 2022 Preclinical trials in Neurological disorders in Italy (unspecified route) (Angelini pipeline, March 2022)